A novel lipid nanocarrier for insulin delivery: Production, characterization and toxicity testing

Pharmaceutical Development and Technology

Volumn 18, Issue 3, 2013, Pages 545-549

  Fangueiro, J F ^a   Gonzalez Mira, E ^b   Martins Lopes, P ^c   Egea, M A ^b   Garcia, M L ^b   Souto, S B ^d   Souto, E B ^a,c  

^a UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Centre of Genomics and Biotechnology   (Portugal)

^d University of Porto   (Portugal)

Author keywords

Drosophila melanogaster; Insulin; Nanocarriers; Nanotoxicology; Softisan 100; Solid lipid nanoparticles

Indexed keywords

INSUMAN COMB; NANOCARRIER; PHOSPHATIDYLCHOLINE; PLACEBO; POLYSORBATE 80; RECOMBINANT HUMAN INSULIN; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DROSOPHILA MELANOGASTER; FEMALE; LIGHT SCATTERING; MALE; MICROSCOPY; MOLECULAR STABILITY; NANOEMULSION; NONHUMAN; PARTICLE SIZE; POLARIZATION; PRIORITY JOURNAL; SOYBEAN; TOXICITY TESTING;

ANIMALS; CRYSTALLIZATION; DROSOPHILA MELANOGASTER; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INSULIN; MALE; NANOCAPSULES;

EID: 84875410964     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2011.591804     Document Type: Article

References (41)

1. Kisel MA, Kulik LN, Tsybovsky IS, Vlasov AP, Vorob'yov MS, Kholodova EA et al. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int J Pharm 2001; 216: 105-114.
2. Prego C, García M, Torres D, Alonso MJ. Transmucosal macromolecular drug delivery. J Control Release 2005; 101: 151-162.
3. Yang R, Gao R, Li F, He H, Tang X. The influence of lipid characteristics on the formation, in vitro release, and in vivo absorption of protein-loaded SLN prepared by the double emulsion process. Drug Dev Ind Pharm 2011; 37: 139-148.
4. Woitiski CB, Neufeld RJ, Ribeiro AJ, Veiga F. Colloidal carrier integrating biomaterials for oral insulin delivery: Influence of component formulation on physicochemical and biological parameters. Acta Biomater 2009; 5: 2475-2484.
5. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007; 59: 478-490.
6. Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. Int J Nanomedicine 2007; 2: 595-607.
7. Gallarate M, Trotta M, Battaglia L, Chirio D. Preparation of solid lipid nanoparticles from W/O/W emulsions: preliminary studies on insulin encapsulation. J Microencapsul 2009; 26: 394-402.
8. Hu FQ, Hong Y, Yuan H. Preparation and characterization of solid lipid nanoparticles containing peptide. Int J Pharm 2004; 273: 29-35.
9. Garcia-Fuentes M, Torres MR, Alonso JM. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloid Surf B 2002; 27: 159-168.
10. Souto EB, Muller RH. Lipid nanoparticles (SLN and NLC) for drug delivery nanoparticles for pharmaceutical applications. Berlin: American Scientific Publishers, 2006, 103-122.
11. Zhang N, Ping QN, Huang GH, Xu WF. Investigation of lectinmodified insulin liposomes as carriers for oral administration. Int J Pharm 2005; 294: 247-259.
12. Harms M, Muller-Goymann CC. Solid lipid nanoparticles for drug delivery. J Drug Deliv Sci Technol 2011; 21: 89-99.
13. Moeller EH, Jorgensen L. Alternative routes of administration for systemic delivery of protein pharmaceuticals. Proteins Therap 2008; 5: 89-94.
14. Khafagy el-S, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev 2007; 59: 1521-1546.
15. Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 2008; 34: 1394-1405.
16. Avadi MR, Sadeghi AM, Mohammadpour N, Abedin S, Atyabi F, Dinarvand R et al. Preparation and characterization of insulin nanoparticles using chitosan and Arabic gum with ionic gelation method. Nanomedicine 2010; 6: 58-63.
17. Carino GP, Mathiowitz E. Oral insulin delivery. Adv Drug Deliv Rev 1999; 35: 249-257.
18. Hinchcliffe M, Illum L. Intranasal insulin delivery and therapy. Adv Drug Deliv Rev 1999; 35: 199-234.
19. Choi JY, Ramachandran G, Kandlikar M. The impact of toxicity testing costs on nanomaterial regulation. Environ Sci Technol 2009; 43: 3030-3034.
20. Philbert MA, Sayes CM, Charlene AM. Nanotoxicology. Comprehensive Toxicology. Oxford: Elsevier, 2011, 707-715.
21. Suh WH, Suslick KS, Stucky GD, Suh YH. Nanotechnology, nanotoxicology, and neuroscience. Prog Neurobiol 2009; 87: 133-170.
22. Müller RH, Gohla S, Keck CM. State of the art of nanocrystals-special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm 2011; 78: 1-9.
23. Kunzmann A, Andersson B, Thurnherr T, Krug H, Scheynius A, Fadeel B. Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. Biochim Biophys Acta 2011; 1810: 361-373.
24. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165-196.
25. Muller RH, Mehnert W, Souto EB. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for dermal delivery. Int J Clin Pharm 2005, 366, 170-184.
26. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004; 56: 1257-1272.
27. Souto EB, Doktorovová S, Boonme P. Lipid nanocarriers-based semisolids: Review on materials and end product formulations. J Drug Deliv Sci Technol 2011; 21: 43-54.
28. Carson H. The ecology of Drosophila breeding sites. Harold Lyon Arboretum Lecture, University of Hawaii, 1971, 1-28.
29. Gaivão I, Sierra LM, Comendador MA. The w/w+ SMART assay of Drosophila melanogaster detects the genotoxic effects of reactive oxygen species inducing compounds. Mutat Res 1999; 440: 139-145.
30. Molnar C, Terriente A, Celis J. Drosophila as a model system for genetic and genomic research. Mol Cell Biol 2006; 26: 2965-2975.
31. Bubliy OA, Loeschcke V. Effect of low stressful temperature on genetic variation of five quantitative traits in Drosophila melanogaster. Heredity 2002; 89: 70-75.
32. García-Fuentes M, Torres D, Alonso MJ. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf B 2003; 27: 159-168.
33. Cournarie F, Savelli MP, Rosilio V, Bretez F, Vauthier C, Grossiord JL et al. Insulin-loaded W/O/W multiple emulsions: comparison of the performances of systems prepared with medium-chaintriglycerides and fish oil. Eur J Pharm Biopharm 2004; 58: 477-482.
34. Sarmento B, Martins S, Ferreira D, Souto EB. Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomedicine 2007; 2: 743-749.
35. Zhang N, Ping Q, Huang G, Xu W, Cheng Y, Han X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm 2006; 327: 153-159.
36. Crystallinity of Dynasan®114 and Dynasan®118 matrices for the production of stable Miglyol®-loaded nanoparticles, 2011 [database on the Internet].
37. Souto EB, Müller RH. Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J Microencapsul 2006; 23: 377-388.
38. Souto EB, Müller RH. SLN and NLC for topical delivery of ketoconazole. J Microencapsul 2005; 22: 501-510.
39. Rogosic M, Mencer HJ, Gomzi Z. Polydispersity index and molecular weight distributions of polymers. Eur Polym J 1996; 32: 1337-1344.
40. Hirth F. Drosophila melanogaster in the study of human neurodegeneration. CNS Neurol Disord Drug Targets 2010; 9: 504-523.
41. Lloyd TE, Taylor JP. Flightless flies: Drosophila models of neuromuscular disease. Ann N Y Acad Sci 2010; 1184: e1-20.